Menu Search
Equities

Avacta Group PLC

AVCT:LSE

Avacta Group PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)49.00
  • Today's Change-1.00 / -2.00%
  • Shares traded1.64m
  • 1 Year change-66.44%
  • Beta1.8197
Data delayed at least 20 minutes, as of Nov 08 2024 16:35 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in GBPIncome statement in GBPView more

Year on year Avacta Group PLC grew revenues 140.83% from 9.65m to 23.25m while net income improved from a loss of 36.63m to a smaller loss of 24.95m.
Gross margin42.08%
Net profit margin-114.45%
Operating margin-149.13%
Return on assets-29.24%
Return on equity-73.02%
Return on investment-61.16%
More ▼

Cash flow in GBPView more

In 2023, cash reserves at Avacta Group PLC fell by 25.15m. Cash Flow from Financing was negative, which signals that this company did not need to attract significant financing from outside sources. In addition the company used 14.87m for operations while cash used for investing totalled 9.00m.
Cash flow per share-0.0728
Price/Cash flow per share--
Book value per share0.1334
Tangible book value per share0.0498
More ▼

Balance sheet in GBPView more

Avacta Group PLC has a Debt to Total Capital ratio of 38.75%, a higher figure than the previous year's 21.73%.
Current ratio1.29
Quick ratio1.21
Total debt/total equity0.6326
Total debt/total capital0.3875
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.